Tonix Pharmaceuticals (TNXP) Stock Climbs On COVID-19 News

Tonix Pharmaceuticals TNXP Stock News

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is making a run for the top in the market this morning, and for good reason. The company announced a research collaboration surrounding horsepox-based vaccines for COVID-19. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

TNXP Stock Heads Up On COVID-19 Vaccine Research Collaboration

In the release, Tonix Pharmaceuticals said that it has entered into an agreement with the University of Alberta. The research collaboration and licensing agreement is centered around the development of three new novel coronavirus vaccine candidates.

These candidates were developed using the horsepox vector platform. However, these particular candidates express different SARS-CoV-2 antigens than TNX-1800, a candidate designed to express SARS-CoV-2 Spike protein.

As part of the agreement, TNXP said that it has been granted an exclusive license from the University of Alberta for technology and patents relating to TNX-1810, TNX-1820, and TNX-1830. All three candidates are being developed as preventatives against COVID-19.

In a statement, Seth Lederman, M.D., President and CEO at TNXP, had the following to offer:

We are excited to expand our pipeline and look forward to developing three additional potential vaccines, TNX-1810, TNX-1820 and TNX-1830 to protect against COVID-19. We are delighted to extend our relationship with David Evans, Ph.D., FCAHS, Professor and former Vice-Dean (Research) Faculty of Medicine and Dentistry at the University of Alberta and principal investigator of the TNX-1810, TNX-1820 and TNX-1830 research project, and Ryan Noyce, Ph.D., Research Associate in Professor Evans’ laboratory at the University of Alberta. Drs. Evans and Noyce synthesized horsepox, which is now our TNX-801 potential vaccine for smallpox and monkeypox. Horsepox is the vector system that is the backbone of the TNX-1800 vaccine that is designed to express the SARS-CoV-2 Spike protein, which Tonix is developing for the prevention of COVID-19 in collaboration with the Southern Research Institute. Horsepox is also the vector system for the new TNX-1810, TNX-1820 and TNX-1830 vaccines. TNX-801 is designed to elicit predominantly T cell responses, while the new vaccines are designed to elicit almost purely T cell responses.

This News Is Exciting

The news released today was overwhelmingly positive for Tonix Pharmaceuticals. While the United States races to reopen the economy, the COVID-19 pandemic is still far from over. Hopes are that a vaccine will be developed in short order, leading to the prevention of further spread of the condition.

As such, there are several companies in the race to develop a vaccine. TNXP has been one in the race from very early on. With the news released today, the company now has three more dogs in the fight.

Should its original vaccine candidate prove ineffective or unsafe for any reason, there are multiple new assets that the company has to develop. Should any one of these assets prove to be effective in preventing infection by the novel coronavirus, it would have the potential to generate significant revenue, making TNXP a stock that should not be ignored.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.